by sara pugliese | May 22, 2022 | News&events
The VisMederi Group keeps growing: its companies closed 2021 budgets with turnovers of over 25 million Euros. This represents an important result, closing a year still deeply affected by Covid-19 and vaccinations. Other significant numbers: 20% trading profit, 37% ROI...
by sara pugliese | May 17, 2022 | News&events
Important new developments for VisMederi Life Sciences. One of the exclusive tests promoted, related to the evaluation of the anti-SARS-CoV-2 activity of appropriately treated fabrics and surfaces, has now also obtained Accredia accreditation, according to ISO 17025...
by sara pugliese | Oct 9, 2021 | News&events
A new candidate vaccine against Covid-19 to be administered without a needle. It is called LeCoVax2 and, both for its mechanism of action and for its characteristics, it represents an absolute novelty in the battle against Sars-CoV-2. VisMederi and University of Milan...
by sara pugliese | Oct 7, 2021 | News&events
HERE FOR THE ARTICOLE https://www.vismederi.com/cgtns-video-reportage-on-vismederi-at-the-forefront-in-italy-and-in-the-world/...
by sara pugliese | Oct 7, 2021 | News&events
“Among the rolling hills of Tuscany, you can find the laboratories that are at the forefront of the research on the origins of Covid-19 in Italy and in the world”. Thus, the Chinese English-speaking broadcaster CGTN (China Global Television Network) spoke about...
